Navigation Links
The Children's Hospital of Philadelphia receives Grand Challenges Explorations funding
Date:11/7/2011

The Children's Hospital of Philadelphia announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges.

Terri Finkel, M.D., Ph.D., chief of Rheumatology at Children's Hospital and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, will pursue an innovative global health research project, titled "Use of a BET Antagonist to Control and Cure HIV Infection."

Grand Challenges Explorations funds scientists and researchers worldwide to explore ideas that can break the mold in how we solve persistent global health and development challenges. Dr. Finkel's project is one of 110 Grand Challenges Explorations grants announced today.

"We believe in the power of innovationthat a single bold idea can pioneer solutions to our greatest health and development challenges," said Chris Wilson, Director of Global Health Discovery for the Bill & Melinda Gates Foundation. "Grand Challenges Explorations seeks to identify and fund these new ideas wherever they come from, allowing scientists, innovators and entrepreneurs to pursue the kinds of creative ideas and novel approaches that could help to accelerate the end of polio, cure HIV infection or improve sanitation."

Projects that are receiving funding show promise in tackling priority global health issues where solutions do not yet exist. This includes finding effective methods to eliminate or control infectious diseases such as polio and HIV as well as discovering new sanitation technologies.

To learn more about Grand Challenges Explorations, visit www.grandchallenges.org.

Dr. Finkel and her research team will study the potential of drugs called synthetic BET (bromodomain extra terminal) family protein antagonists to control HIV infection and latency. Current HIV drugs reduce the disease-causing virus to undetectable levels, but the virus goes into a dormant state called latency, from which it can make a resurgence if a patient stops taking medication. Previous studies by Dr. Finkel and other scientists have suggested that BET antagonists may flush HIV out of its hiding places where it can be destroyed by other antiretroviral drugs.

Dr. Finkel's chief collaborator in this project is Gerd A. Blobel, M.D., Ph.D., holder of the Frank E. Weise III Endowed Chair in Pediatric Hematology at The Children's Hospital of Philadelphia, who has focused on the biological activities of BET family proteins. In the first part of the project, Drs. Finkel and Blobel will investigate the effectiveness of BET antagonists against HIV in cell cultures. If these results are encouraging, the project will progress to clinical trials in patients with HIV. Because this class of drugs will soon be tested in humans as treatments for other diseases, appropriate BET antagonists are expected to be freely available for HIV clinical trials.


'/>"/>

Contact: John Ascenzi
ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
2. Parents Want Electronic Access to Their Childrens Docs: Survey
3. Prostate cancer surgery better at teaching hospitals
4. Hospital for special surgery physician-scientists share advances in rheumatology research
5. Latex gloves lead to lax hand hygiene in hospitals, study finds
6. Hospital Rooms Crawling With Drug-Resistant Germs: Study
7. Shorter hospital stay with person-centered healthcare
8. Drugs used to tackle hospital-acquired infections can increase post-op complications
9. Study finds no link between elderly patient activity and hospital falls
10. Hospital team significantly reduced risk of further vascular events after mini strokes
11. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... to treat wrinkles and deep lines by smoothing and tightening the skin of ... techniques out there to address facial aging with very little downtime, Silhouette Instalift ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning ... to an emergency medical call when he lost control of his patrol car. The ... from his vehicle, he was transported to Atlanta Medical Center, where he later succumbed ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Castle Dermatology Institute ... several ways to restore a more youthful appearance to the face. Dr. Peyman Ghasri ... along with a variety of other treatments, to rejuvenate and renew the facial appearance. ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Biosimilar Clinical Trial & Opportunity Insight" report by PNS Pharma gives comprehensive ... Currently 5 biosimilar version of Lantus are commercially available in ... , Czech Republic , Estonia , ... Slovakia , United Kingdom for the treatment ... in 2014. Lantus is the brand name for Insulin Glargine, a ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... -- A new investigational drug originally developed for type 2 ... of the world,s first treatment to impede the progression of ... in the journal Science Translational Medicine . ... for millions of people living with Parkinson,s disease," says ... Research Institute,s Center for Neurodegenerative Science , chairman ...
Breaking Medicine Technology: